KLK3 and Familial prostate cancer: In this meta-analysis, we found that patients with localized or locally advanced nonmetastatic, high-grade prostate cancer with low PSA levels (<4 ng/mL) had a nonsignificant reduction in the risk of both PCSM and ACM when docetaxel was added to the SOC therapies of testosterone suppression plus radiotherapy or RP.